Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.35 |
| ▸ | STK3 | Q13188 | 8/20 | 0.35 |
| ▸ | STK4 | Q13043 | 6/20 | 0.35 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | ROS1 | P08922 | 2/20 | 0.35 |
| ▸ | MARK3 | P27448 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | MELK | Q14680 | 2/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422496 | 0.75 | STK3 (0.61) | CHEK1JAK3PDPK1LRRK2STK3 | |
| SCHEMBL29378308 | 0.70 | LRRK2 (0.61) | CHEK1JAK3PDPK1CDK2CDK5 | |
| SCHEMBL3226104 | 0.70 | LRRK2 (0.61) | CHEK1JAK3PDPK1CDK2CDK5 | |
| SCHEMBL1598149 | 0.69 | CHEK1 (0.66) | CHEK1JAK3CDK2CDK9CDK5 | |
| SCHEMBL31329069 | 0.69 | CHEK1 (0.66) | CHEK1JAK3CDK2CDK9CDK5 | |
| SCHEMBL16636871 | 0.69 | LRRK2 (0.61) | CHEK1JAK3CDK2CDK5LRRK2 | |
| SCHEMBL28613532 | 0.69 | GPR84 (0.44) | JAK3PDPK1CDK2CDK9CDK5 | |
| SCHEMBL7060408 | 0.68 | STK3 (0.56) | CHEK1JAK3PDPK1CDK2CDK9 | |
| SCHEMBL153752 | 0.68 | CHEK1 (0.63) | CHEK1JAK3LRRK2STK3STK4 | |
| SCHEMBL2323682 | 0.68 | CHEK1 (0.63) | CHEK1JAK3CDK2CDK9CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | CHEK1 1915/4885JAK3 1750/4885PDPK1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.